The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L-Reference-Cited by-同舟云学术

The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L

Published:2021-09 Issue: Volume:137 Page:31-44
ISSN:0895-4356
Container-title:Journal of Clinical Epidemiology
language:en
Short-container-title:Journal of Clinical Epidemiology

Author:

Gamper Eva M.,Cottone Francesco,Sommer Kathrin^ORCID,Norman Richard,King Madeleine,Breccia Massimo,Caocci Giovanni,Patriarca Andrea,Palumbo Giuseppe A.^ORCID,Stauder Reinhard,Niscola Pasquale^ORCID,Platzbecker Uwe,Caers Jo,Vignetti Marco,Efficace Fabio

Publisher

Elsevier BV

Subject

Epidemiology

Reference63 articles.

1. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet;Malcovati;Blood Vol,2013

2. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs;Rollison;Blood,2008

3. No increase in age-specific incidence of myelodysplastic syndromes;Germing;Haematologica,2004

4. The incidence of myelodysplastic syndromes in Western Greece is increasing;Avgerinou;Ann Hematol,2013

5. https://seer.cancer.gov/csr/1975_2017/results_merged/sect_30_mds.pdf#search=mds 2021.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the reliability of a novel cancer-specific multi-attribute utility instrument (FACT-8D) and comparing its validity to EQ-5D-5L in colorectal cancer patients;Quality of Life Research;2024-09-03

2. Valuing quality of life for economic evaluations in cancer: navigating multiple methods;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-19

3. Quality of life considerations in myelodysplastic syndrome: not only fatigue;Expert Review of Hematology;2024-07-12

4. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs;PharmacoEconomics - Open;2024-05-02

5. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands;The European Journal of Health Economics;2024-03-14